FDA 483 OBSERVATION · #855 OF 1,932 MOST-CITED
Return to inventory--procedures
FDA cited this observation 22 times across 22 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
How FDA worded it — real examples
Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established, defined and documented.
Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not documented.
Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established.
Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established and implemented.
Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not established.
Procedures for determining if HCT/Ps that were returned to the establishment are suitable to be returned to inventory were not defined, implemented and followed.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →